Trial reportFrontiers in immunology2022
Probiotics modulate gastrointestinal microbiota after
Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Impact of probiotic supplementation on salivary function, oral microbiota, and gut health: a systematic review.Frontiers in cellular and infection microbiology · 2026Pooled it
- Efficacy of probiotics pretreatment inAnnals of medicine · 2025Pooled it
- The effect of supplementing withFrontiers in medicine · 2024Pooled it
- AdjuvantMicrobiology spectrum · 2026Trial
- Probiotics alleviate oral microbiota disruptions induced byFrontiers in cellular and infection microbiology · 2026Trial
- Use of WeChat-based patient-doctor interaction improves patient experience ofFrontiers in digital health · 2026Trial
- Multistrain probiotics alleviate gastrointestinal symptoms during bismuth quadruple therapy forWorld journal of gastroenterology · 2025Trial
- Impact of supplementing Limosilactobacillus fermentum MN-LF23 on the eradication of Helicobacter pylori with 14-day standard quadruple therapy: a randomized, double-blind, placebo-controlled trial.Nutrition journal · 2025Trial
- Trial
- Evaluation of efficacy and safety ofFrontiers in immunology · 2024Trial
- Exploration of the Interaction Between Bismuth-Containing Quadruple Anti-Microorganisms · 2026Article
- Therapeutic Potential of Probiotics in the Modulation of Antibiotic Resistance inBiomedicines · 2026Review
- Effects of Helicobacter pylori infection on gastric mucosal microbiota.World journal of pediatrics : WJP · 2026Review
- From Eradication to Holistic Regeneration: Pharmaceutics Strategies for Reshaping Gastric Homeostasis AgainstPharmaceutics · 2026Review
- Traditional Chinese medicine alleviate gastrointestinal symptoms during bismuth quadruple therapy forWorld journal of gastroenterology · 2026Article
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- Probiotics and Diet Modifications: A Holistic Approach to Tackling Helicobacter pylori with the Help of the Gut Microbiota.Probiotics and antimicrobial proteins · 2026Review
- Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics.Biomedicines · 2026Review
- Genomic Assessment, Metabolic Profile Mapping, and Anti-Helicobacter pylori Activity of Lactococcus lactis SK2-659 from Thai Fermented Green Mustard (Pak-kad-dong).Probiotics and antimicrobial proteins · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objectives: To evaluate the impact of probiotics on gastrointestinal microbiota after eradication therapy. Methods: This was a multicenter, double-blinded, randomized trial done at seven centers in China. A total of 276 treatment-naïve Results: The incidence of gastrointestinal adverse events was lower in probiotics group compared to placebo group (23.6% vs 37.7%, p=0.016), while there was no significant difference in eradication rate. We found dramatic perturbations of gut microbiota immediately following eradication, with the predominance of Proteobacteria in replacement of commensal Firmicutes and Bacteroidetes, and gradually restored after two weeks. The reduction of gut Bacteroidetes caused by eradication drugs was neutralized with probiotics supplementation. The gastric microbiota was completely reconstituted with Conclusion: This study not only demonstrated the beneficial effect of probiotics implementation on side events during
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.